跳轉至內容
Merck

MAB348-AF555

Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor 555

clone 22C11, from mouse, ALEXA FLUOR 555

同義詞:

Amyloid beta A4 protein, ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II, PN-II, N-APP, Soluble APP-alpha, S-APP-alpha, Soluble APP-beta, S-APP-beta,

登入 查看組織和合約定價

選擇尺寸


關於此項目

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41
技術服務
需要援助?我們經驗豐富的科學家團隊隨時樂意為您提供支援。
讓我們為您提供幫助
技術服務
需要援助?我們經驗豐富的科學家團隊隨時樂意為您提供支援。
讓我們為您提供幫助

生物源

mouse

品質等級

共軛

ALEXA FLUOR 555

抗體表格

purified immunoglobulin

抗體產品種類

primary antibodies

無性繁殖

22C11, monoclonal

物種活性

canine, human, mouse, rat, porcine, monkey, fish

技術

immunocytochemistry: suitable

同型

IgG1

UniProt登錄號

運輸包裝

wet ice

目標翻譯後修改

unmodified

基因資訊

human ... APP(351)

一般說明

Amyloid beta A4 protein (UniProt P05067; also known as ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID 351) in human. Amyloid precursor protein (APP) is initially produced with a signal peptide sequence (a.a. 1-17), the removal of which yields the mature protein with a large extracellular portion (a.a. 18-699), followed by a transmembrane segment (a.a. 700-723) and a cytoplasmic (a.a. 724-770) tail. APP can be further processed by the α-, β-, and γ-secretases in two alternative processing pathways. In the non-amyloidogenic pathway, APP is first cleaved by the plasma membrane-localized α-secretase to generate an N-terminal extracellular sAPPα fragment (a.a. 18-687) and a membrane-bound C-terminal fragment C83 (CTFα), which can be further cleaved by γ-secretase to produce a non-toxic small peptide p3 and a cytoplasmic APP intracellular domain (AICD). In the amyloidogenic pathway, APP undergoes β-cleavage in BACE-1 (β-site APP-cleaving enzyme)-enriched endosomes to generate an N-terminal extracellular sAPPβ fragment (a.a. 18-671) and a membrane-bound C-terminal fragment C99 (CTFβ). Subsequent cleavage of C99 by γ-secretase releases the amyloid β peptide (Aβ) and AICD. Aβ accumulation in the cortical and hippocampal regions of the brain is a major pathological feature of Alzheimer′s disease (AD).
~110/120/130 kDa observed.

免疫原

Epitope: Amino acids 66-81 of APP.
Purified recombinant Alzheimer precursor A4 (pre-A4695) fusion protein.

應用

Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor 555 is an antibody against APP A4 for use in Immunocytochemistry.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
The unconjugated antibody (Cat. No. MAB348) is shown to be suitable also for immunohistochemistry (for both frozen and paraffin-embedded sections), immunofluorescence, and Western blotting applications.

生化/生理作用

Clone 22C11 reacts with pre-A4. The antibody recognizes amino acids 66-81 of the N-terminus on the pre-A4 molecule (Hilbich, C., et al. (1993). J. Biol. Chem. 268(35):26571-26577). Clone 22C11 recognizes all three isoforms of APP, immature ~110kDa, sAPP ~120kDa, and mature ~130kDa (Hoffmann, J., et al. (2000). Eur. J. Cell. Biol.79(12):905-914.). The antibody is known to cross react with APLP2 (Slunt, H.H., et al. (1994). J. Biol. Chem. 269(4):2637-2644).

外觀

Protein A purified
Purified mouse monoclonal IgG1 antibody conjugate in PBS with 15 mg/mL BSA and 0.1 % sodium azide.

準備報告

Stable for 1 year at 2-8°C from date of receipt.

分析報告

Evaluated by Immunocytochemistry in SH-5YSY cells.

Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected APP A4 in SH-5YSY cells.

其他說明

Concentration: Please refer to lot specific datasheet.

法律資訊

ALEXA FLUOR is a trademark of Life Technologies

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

相關內容

Alzheimer’s Disease is a progressively deteriorating disease. It manifests itself with memory loss, confusion, problems with judgment, planning, concentration, and personality changes; and in it’s later stages, a decline in physical abilities. The disease’s causes, cures, and preventions are unknown; however, key proteins likely involved in the degenerative mechanism have been identified. Alzheimer’s Disease is characterized by neuronal loss, alterations in neurotransmitter systems, and the presence of neurofibrillary tangles composed of abnormally hyperphosphorylated tau proteins. A prominent feature of Alzheimer’s Disease is the formation of senile plaques in selected regions of the brain. The center of these plaques are composed mainly of fibrillary aggregates of a common, but not well understood, b amyloid peptides (Aβ). The Aβ peptides are generated from the larger amyloid-β precursor protein (APP) by the sequential action of β- and γ-secretase, and it is generally accepted that oligomeric forms of this Aβ are neurotoxic, resulting in disease progression.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務